The compounds will be evaluated for their use as drugs as well as incorporation into devices.
Ceragenix Pharmaceuticals licensed a family of preclinical anti-HIV compounds to FirstPoint Biotech (FPBT). The transaction includes CSA-54 and other members of the Ceragenin™ group of candidates. Their systemic and topical use as drugs as well as incorporation into medical devices such as condoms, sprays, or gels will be assessed.
FPBT is responsible for clinical development and commercialization, while Ceragenix will provide consultation. The agreement provides for payment of milestone fees and royalties.
Researchers from Vanderbilt University found that CSA-54 potently inhibits HIV infection of primary human CD4+ T cells and was not toxic to epithelial cells at concentrations higher than those required to kill the virus, according to Ceragenix. The molecule also killed a wide range of HIV isolates and completely blocked genetically engineered HIV that enters the cells independent of cell-surface receptors, the company continues.